iVIEW Therapeutics was awarded SBIR Innovative Year 2 Grant by NIH’s National Institute of Allergy and Infectious Diseases (NIAID)

Doylestown, Pennsylvania–iVIEW Therapeutics Inc., a clinical-stage biotechnology company focusing on topical drug development on the areas of ophthalmology, otolaryngology, and dermatology, today announced that it has been awarded a Small Business Innovation Research (SBIR) Year 2 Award of $300,000 from National Institute of Allergy and Infectious Diseases (NIAID) at National Institutes of Health (NIH). This phase I SBIR Year 2 grant is awarded based on iVIEW’s successful completion of its Year 1 project since April 1, 2018. iVIEW’s project is titled “In-situ gel of Povidone Iodine/Budesonide as Sustained Nasal Drug Delivery for the Treatment of Chronic Rhinosinusitis”. “If successful, this combination of a long acting broad anti-infective with an anti-inflammatory agent is likely to have a significant impact on treatment of patients with chronic rhinosinusitis (CSR)”, commented by the NIH reviewers. Dr. Bo Liang, Chairman & President at iVIEW comments, “The continuation of SBIR award showed the confidence of the agency towards our innovation and project progress. In the Grant Year 2 period, we will progress quickly though pre-clinical studies and plan to file US IND in the year of 2020 to move into clinical development.”

5 Cedarbrook Drive, Suite 2
Cranbury, NJ 08512, USA
Copyright © 2022 iVIEW Therapeutics, Inc. All rights reserved.